## Amendments to the Claims

Please <u>cancel</u> claims 2-3 and 12-13 without prejudice or disclaimer, and amend the claims as listed below.

The listing of claim will replace all prior versions and listings of claims in the application:

## Listing of claims:

Claim 1. (currently amended) <u>Isolated An isolated human DCR5</u> protein, <u>having the amino acid</u> sequence as set forth in SEQ ID NO: 12.

## Claim 2-3. Canceled

- 4. (currently amended) An <u>isolated</u> antibody which specifically binds the isolated human DCR5 protein of claim 1.
- 5. (original) The antibody of claim 4, which is a monoclonal antibody.
- 6. (original) A composition comprising the human DCR5 protein of claim 1, in a pharmaceutically acceptable carrier.
- 7. (original) A composition comprising the antibody of claim 4, in a pharmaceutically acceptable carrier.
- 8. (original) A human DCR5 protein produced by the method of:
- a) constructing a vector comprising a nucleic acid molecule containing a nucleotide sequence encoding human DCR5 protein as set forth in SEQ ID NO: 12, wherein the nucleic acid molecule is operatively linked to an expression control sequence capable of directing its expression in a host cell;
  - b) introducing the vector of (a) into a host cell;

USSN 10/662,756 Response dated 1 June 2004 Reply to Office action dated 28 April 2004

- c) growing the host cell of (b) under conditions which permit the production of human DCR5 protein; and
  - d) recovering the human DCR5 protein so produced.
- 9. (currently amended) The protein of claim [7] 8, wherein the host cell is a bacterial, yeast, insect or mammalian cell.
- 10. (original) The human DCR5 protein of claim 1, fused to an immunoglobulin constant region.
- 11. (original) The human DCR5 protein of claim 10, wherein the immunoglobulin constant region is the Fc portion of human IgG1.

Claims 12-13. Canceled